Current status of rectal cancer treatment in <scp>C</scp>hina

Gu, Jin; Chen, N.

doi:10.1111/codi.12269

Cited by 45 publications

(30 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first National Guideline for the Diagnosis and Treatment of Colorectal Cancer in China, which referred to the US National Comprehensive Cancer Network (NCCN) guideline, was published in 2010. Prior to 2010, the treatment scheme for locally‐advanced low and middle rectal cancers in China was different to that in Western countries . Treatment for elderly patients with metastatic colorectal cancer is complex and varies depending on the age, performance status, comorbidities and personal wishes of the patient.…”

Section: Discussionmentioning

confidence: 99%

A population‐based study elicits a reverse correlation between age and overall survival in elderly patients with rectal carcinoma receiving adjuvant chemotherapy

Shan

Ren

et al. 2015

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Colorectal cancer is the third most common cancer and the fourth most common cause of cancer-related death globally. This population-based study aimed to explore the predictive factors that affected the overall survival of rectal cancer patients receiving adjuvant chemotherapy plus radical surgery using a Cox proportional hazards modeling approach. A total of 619 patients with rectal cancer who underwent surgery were enrolled between October 2006 and May 2013. Clinical characteristics of the patients were compared among the groups and potential prognostic factors were analyzed using the spss program, version 19.0. Patients aged ≥ 70 years have distinctive characteristics such as lager tumour size (≥ 5 cm), damaged micturition and higher incidence of diabetes compared to younger and middle-aged patients. Male gender, tumour size (≥ 5 cm), poor differentiation, later stage, adjuvant chemotherapy, damaged micturition, hypertension or diabetes are associated with a worse prognosis for rectal cancer patients (P < 0.05). However, smoking is a favourable factor to the patients (P = 0.018). Age of ≥ 70 years is an independent prognostic factor for patients with rectal cancer after surgery (P = 0.000) and elderly patients with Stage II and III disease receiving adjuvant chemotherapy show a favourable prognosis. The elderly patients who suffered from diabetes receiving adjuvant chemotherapy have a poor prognosis. Further prospective and large population studies are warranted to confirm the findings of this study.

show abstract

Section: Discussionmentioning

confidence: 99%

A population‐based study elicits a reverse correlation between age and overall survival in elderly patients with rectal carcinoma receiving adjuvant chemotherapy

Shan

Ren

et al. 2015

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…Surgical excision of CRC is carried out in almost all hospitals in China, including those at the national level. In accordance with international guidelines, Chinese guidelines advocate neoadjuvant chemoradiotherapy for advanced CRC . Adjuvant chemotherapy may be important in reducing the incidence of local recurrence and metastasis .…”

Section: What Is Known and Objectivementioning

confidence: 99%

Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer

Wang

Tian

et al. 2016

J Clin Pharm Ther

View full text Add to dashboard Cite

Summary What is known and Objective Research has indicated that some Chinese herb injections (CHIs) might be beneficial in combination with chemotherapy, including remedies that might be used as effective chemosensitizers and radiosensitizers, or as palliative therapy. Here, we carried out a network meta‐analysis to assess the clinical efficacy and safety of CHIs combined with oxaliplatin, 5‐fluorouracil and leucovorin (FOLFOX) for advanced colorectal cancer (CRC). Methods PubMed, EMBASE.com, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), Wanfang Database and Chinese Journal Full‐text Database were searched from inception to 31 December 2014, to identify relevant randomized controlled trails (RCTs). The risk of bias in included RCTs was evaluated according to the Cochrane Handbook version 5.1.0. Standard pairwise meta‐analysis and Bayesian network meta‐analysis were performed to compare the efficacy and safety of different CHIs combined with FOLFOX. Data were analysed using STATA 12.0 and WinBUGS1.4 software. Results and discussion We identified 63 eligible studies (with 4837 patients in total), involving 9 CHIs. Pairwise meta‐analysis showed that compared with FOLFOX alone, combinations with Aidi injection and compound matrine injection could significantly improve the overall response rate and quality of life and reduce the incidence of nausea and vomiting (III‐IV), diarrhoea (III–IV), thrombocytopenia (III–IV), leukopenia (III–IV) and peripheral neurotoxicity (III–IV). According to results of indirect comparison, there were no statistically significant differences for most of comparison groups. Aidi+FOLFOX, shenqifuzheng+FOLFOX and compound matrine+FOLFOX had the greatest probability of being the best treatment in clinical efficacy and safety, considering the small sample size. What is new and Conclusions Most of the included studies were of low quality, and there was a scarcity of eligible trials and numbers of participants. Based on currently limited evidence, aidi, shenqifuzheng and compound matrine were superior to other CHIs in patients receiving FOLFOX chemotherapy for advanced CRC. More studies are required to confirm the efficacy of CHIs in combination with FOLFOX for advanced CRC.

show abstract

“…Colorectal cancer (CRC) is the fourth common carcinoma in China, and the morbidity is also increasing rapidly (Gu et al, 2013). Similar situation also appears in other countries (Abdifard et al, 2013).…”

Section: Introductionmentioning

confidence: 62%

Prognostic Significance of the Mucin Component in Stage III Rectal Carcinoma Patients

Wang¹,

Zhang²,

Yang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

Current status of rectal cancer treatment in China

Cited by 45 publications

References 44 publications

A population‐based study elicits a reverse correlation between age and overall survival in elderly patients with rectal carcinoma receiving adjuvant chemotherapy

A population‐based study elicits a reverse correlation between age and overall survival in elderly patients with rectal carcinoma receiving adjuvant chemotherapy

Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer

Prognostic Significance of the Mucin Component in Stage III Rectal Carcinoma Patients

Contact Info

Product

Resources

About